Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It is not classified as a serious adverse effect and does not typically warrant discontinuation of therapy
however, many existing diagnostic cut-offs were developed in older adults and may not apply to younger populations, highlighting the need for updated studies to validate these tools during treatment with obesity medications [24]
Lower betaine intake is associated with lower insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR) (57), and an increased risk of other T2DM (58)
And you know, I have a feeling that there was a reason why they didnt
The titration regimen described in the NEJM 2023 obesity trial (Jastreboff et al.) progressed as follows: Weeks 14 : 2 mg once weekly Weeks 58 : 4 mg once weekly Weeks 912 : 8 mg once weekly Week 12 onwards : Up to 12 mg once weekly (in higher-dose cohorts) This regimen was used exclusively within a regulated clinical trial setting and does not constitute an approved dosing schedule
